2nd Annual Dermatology Drug Development Summit in Boston November 27-29
Fluicell presents disease-relevant tissue formation from Biopixlar printing platform at 2nd Annual Dermatology Drug Development Summit in Boston November 27-29
Fluicell announces that they have produced new application data using their Biopixlar bioprinting prototype platform that will be presented at the 2nd Annual Dermatology Drug Development Summit in Boston November 27-29.
For this summit, the data to be presented includes high precision printing of a variety of different cell types that show excellent survivability that allows for long-term culture.
Most significantly, Fluicell will show complex tissue formation from co-printing of human skin cancer and skin epithelial cells that directly can be used for drug screening and other biomedical applications.
The state-of-the art data is a landmark milestone for the the Biopixlar platform to generate disease-relevant tissue models that Fluicell believes has the capability of transforming drug development practices. The company says that they are now ready to enter into Biopixlar service and application collaborations with the industry, clinics and universities.
We look forward to welcoming you at DDDS 2018 for our presentation the 28th of November at 12h45.
Meet Dr. Tatsiana Lobovkina, our CSO and Dr. Gavin Jeffries, our CTO at our booth for more information.